Troubled Illinois-based pharmaceutical company Akorn steeply raised prices of at least a dozen drugs last month to try to offset several financial setbacks, according to STAT.

Hospital and health system pharmacy leaders are tasked with overcoming complex challenges in today's increasingly dynamic reimbursement environment, including managing the skyrocketing costs of medications and mitigating the effects of drug shortages.

Effective Jan. 1, 2020, CVS Caremark will no longer serve as the pharmacy benefit manager of Ohio's largest Medicaid managed care provider, according to The Columbus Dispatch.

OptumRx released a list of five new and potentially expensive treatments coming to the market in 2019 that healthcare companies should pay attention to. They're listed below:

A physician who once helped Purdue Pharma drive the adoption of OxyContin in the healthcare industry has agreed to testify against the drugmaker, according to CNBC.

The Senate Finance Committee's April 9 hearing with executives from five major pharmacy benefit managers should lead to a bill that will end the "secrecy" in the drug industry and cause drug prices to drop, Chairman Sen. Chuck Grassley, R-Iowa,…

In an atypical move, House Republicans sent letters to a dozen drugmakers warning that compliance with a House panel investigation into drug prices could hurt their stock prices.

After discontinuing work on its sole drug candidate in a clinical trial, Cambridge, Mass.-based Merrimack Pharmaceuticals will complete another round of layoffs, according to The Boston Business Journal.

The Bay Clinic, a primary care provider with eight locations in East Hawaii, opened its first in-house pharmacy last week, according to the Hawaii Tribune-Herald.

Pharmacy benefit managers, the middlemen who negotiate drug benefits for health plans, will head to Capitol Hill this week to face back-to-back hearings about their role in the pricing of prescription drugs.